Search research articles
Contact Us
Filters
Showing results (391-400 of 512) with videos related to
Page
of 52
Sort By:
British Journal of Cancer
|
December 14, 2023
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
Jordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network
Arthur Petat, Eric Dansin, Fabien Calcagno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C Arbour, Laura Mezquita, Niamh Long, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
Arthur Géraud, Thomas Hueso, Ariane Laparra, et al.
British Journal of Cancer
|
September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis
Abderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.
Nature Medicine
|
May 15, 2020
Caring for patients with cancer in the COVID-19 era
Joris van de Haar, Louisa R Hoes, Charlotte E Coles, et al.
Page
of 52
Search research articles
Search
Showing results (391-400 of 512) with videos related to
Sort By:
Page
of 52
British Journal of Cancer
|
December 14, 2023
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
Sophie Postel-Vinay, Juan Coves, Matthieu Texier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
Jordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 29, 2021
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network
Arthur Petat, Eric Dansin, Fabien Calcagno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2018
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C Arbour, Laura Mezquita, Niamh Long, et al.
The Oncologist
|
April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 Analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist
|
May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis
Alexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 11, 2024
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
Arthur Géraud, Thomas Hueso, Ariane Laparra, et al.
British Journal of Cancer
|
September 10, 2025
Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis
Abderaouf Hamza, Pierre Gestraud, Maryam Karimi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.
Nature Medicine
|
May 15, 2020
Caring for patients with cancer in the COVID-19 era
Joris van de Haar, Louisa R Hoes, Charlotte E Coles, et al.
Page
of 52